Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs

Dear Consultees and commentators,

Following the invitation to participate in the STA of golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs the manufacturer of golimumab informed us that they are not in a position to submit evidence in line with the current schedule for this STA.

This is because not all information is available to complete an evidence submission at this stage. This STA is therefore suspended. NICE anticipates that evidence will be submitted in the near future, but because of this delay NICE is not in a position to issue timely guidance.

We will inform you when the STA of golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs can be re-scheduled.

If you have any questions please contact me on 020 7045 2248 or by email, jeremy.powell@nice.org.uk.

Kind regards,

Jeremy

Jeremy Powell
Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom
Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830